A Young Nigerian Doctor Gains Global Recognition for Innovative Joint Disease Treatment

A Young Nigerian Doctor Gains Global Recognition for Innovative Joint Disease Treatment

Dr. Maduka Abara, a young Nigerian doctor, has gained international acclaim and received a prestigious award from the medical community for developing a revolutionary product that treats joint diseases. His groundbreaking discovery is helping millions worldwide to prevent conditions like osteochondrosis, arthritis, osteoarthritis, and related complications, including blood poisoning caused by joint diseases.

On July 29, 2024, something remarkable occurred at the European Congress of Rheumatologists. Dr. Maduka Abara received a standing ovation that lasted 19 minutes, as he presented his unique formula designed to treat joint diseases at any age and prevent the complete deterioration of joints.

Dr. Abara's innovative idea was brought to life with the support of Nigeria's scientific community, involving experts from leading clinics and research centers across the country. The initial results of this collaborative effort have been outstanding.

**Reporter:** Good afternoon, Dr. Abara. You are recognized as one of the world's ten smartest medical students. What inspired you to specialize in joint diseases?

**Dr. Abara:** My motivation is deeply personal, and I'd prefer not to elaborate too much. A few years ago, my mother suffered from blood poisoning due to deteriorating joints. Initially, she experienced mild joint pain, which I didn't take seriously because she didn't express the extent of her pain. Unfortunately, after a doctor misdiagnosed her and prescribed the wrong medication, she developed blood poisoning and passed away.

For the past three years, I've been researching joint diseases. During this time, I discovered a new treatment method that has since gained widespread attention. I realized that I had stumbled upon something completely new, but I was surprised by the overwhelming interest from various institutions.

My grandmother also died from a similar illness. This tragic experience led me to study joint diseases and treatments. I was shocked to learn that most products sold in pharmacies are ineffective chemicals that worsen the condition. My mother had been taking them daily.

**Reporter:** We heard that international pharmaceutical companies have shown interest in your product. Have they made any offers to buy it from you?

**Dr. Abara:** As soon as word spread about my treatment, I began receiving offers to sell my idea. A French company initially offered me $120,000, and later, an American pharmaceutical giant offered $35 million. I had to change my phone number and avoid social media due to the overwhelming number of offers.

**Reporter:** But you didn't sell it, did you?

**Dr. Abara:** No, I didn't. It may sound harsh, but I didn't develop this product just for international companies to profit from it. If I sold it to a foreign company, they would patent it, and the price would skyrocket. I'm young, but I'm not naive. Under those conditions, most Nigerians wouldn't be able to afford the treatment. One foreign doctor even suggested the price could reach $3,000, which is absurd. Who in Nigeria can afford that?

When a local medical center offered to produce the treatment in Nigeria, I immediately agreed. We collaborated with experts from the country's top medical centers, and the experience was incredible. The product has passed all clinical tests and is now available for purchase.

At the medical center, the Director of Production was Dr. Igwebuike Abiola from the Rheumatologic Centre, an expert with 20 years of experience. We asked him to share more about the product and its future prospects.

**Reporter:** Dr. Abiola, can you provide more details on the development of this new product, both as a rheumatologist and an expert in the field? How does Maduka Abara's product work, and does it truly help restore joints at any age?

**Dr. Abiola:** Maduka's approach is groundbreaking, even in cases of hereditary joint disease. It's well-known among specialists that most pharmaceutical products today only help in the early stages. Unfortunately, some doctors prescribe numerous drugs that merely delay the inevitable. When a patient can barely move without pain, they are often sent for surgery. Traditional drugs work ineffectively, are non-selective, and have toxic side effects. They merely mask the symptoms rather than addressing the root cause, ultimately worsening the patient's condition. Maduka's discovery, called Fast Active, supports proper joint restoration. We tested Fast Active cream on a group of 50 patients with varying stages of joint disease. The results were impressive: all patients in the 1st and 2nd stages were completely cured, and 27% of those in the 3rd stage also saw significant improvement. The product restored joints to their normal state, and patients reported relief from pain.

**Reporter:** What are the dangers of joint disease?

**Dr. Abiola:** The first complication of knee arthrosis is long-term inflammation of the surrounding soft tissues. Even in the early stages, patients may develop arthritis, capsulitis, tendinitis, bursitis, and other conditions. These processes cause scarring and deformation of soft tissues, leading to joint instability and potentially ligament ruptures.

The leg on the affected side may shorten as the joint deteriorates, and the surrounding cartilage breaks down. This can lead to improper load distribution, causing further complications in the lumbar spine and sacroiliac joint.

In the early 2000s, our scientists discovered that up to 90% of joint diseases are caused by insufficient blood flow to the joint. This results in cartilage destruction and infection of the bone and surrounding tissue. By addressing the underlying cause, expensive surgeries can often be avoided.

Maduka's idea helps regulate blood flow throughout the musculoskeletal system, eliminating the risk of joint destruction in the early stages. However, more effort is needed to create an effective treatment that restores joint tissue and flexibility, particularly in advanced cases.

**Reporter:** But isn't it true that "reconstructing" a joint is impossible without surgery, especially after the age of 40?

**Dr. Abiola:** That's a misconception, perpetuated by pharmaceutical companies for profit. It's well-known that the human body can regenerate any system with the right support. By reducing inflammation, improving blood flow, and accelerating the removal of dead cells and toxins, joints can be restored without surgery.

**Reporter:** How were joints treated in the past? Aren't there many products available in pharmacies?

**Dr. Abiola:** Yes, there are many products, but they all work on the same principle we discussed earlier. These products only address the symptoms and provide temporary relief. However, they can actually harm the joints in the long run. Maduka was absolutely right. If you examine the formulas of these pharmacy products, it's clear they should only be used as a last resort.

**Reporter:** How is your product different? It seems it can fully restore joint mobility.

**Dr. Abiola:** Fast Active's primary goal is to create new bone and cartilage tissue, replacing damaged tissue and restoring blood flow. Just one application activates over 930,000 cells involved in joint mobility restoration. This is the key principle behind our treatment.

We approached the problem seriously, just as Maduka did. Fast Active isn't just a mix of chemical formulas recycled from other drugs; it's a unique blend of highly concentrated plant extracts. This makes it not only highly effective but also completely safe.

Within just 1-2 days of applying Fast Active, patients showed increased blood flow, restored joint cells and tissues, and improved mobility, even in severe cases. Unlike chemical-laden products, Fast Active doesn't damage the skin or cause allergic reactions.

**Reporter:** Will your product be available in pharmacies? And what will it cost?

**Dr. Abiola:** As soon as it became clear that we had developed something truly effective and long-lasting, pharmacists began attacking us from all sides. They even offered to buy Maduka's formula to prevent it from reaching the market. Joint treatment is one of the most lucrative segments of the pharmaceutical industry, generating billions of dollars annually, especially in the United States. Our product has the potential to revolutionize the market. Once people can take a course of Fast Active and restore joint mobility at any age, they won't need to spend money on outdated drugs or expensive surgeries and joint replacements.

Pharmacies are closely tied to pharmaceutical companies and depend on their sales. So, they don't want to acknowledge our product. But this is the only treatment for joint diseases and complications that has been proven effective in clinical trials.

**Reporter:** If it's not available in pharmacies, how can people get Fast Active?

**Dr. Abiola:** We realized that if traditional pharmacies wouldn't accept us, we could bypass them. We've started direct distribution of Fast Active, independent of commercial pharmacies. We considered several options and chose the most effective one. Anyone interested in buying Fast Active can fill out an application form, and we'll contact them to arrange delivery. Almost everyone has internet access nowadays, whether through a computer or a smartphone.

From August 8 to August 17, 2024, we're offering a promotional discount for Nigerians to try the product. This initiative is part of our effort to raise awareness about Fast Active. We hope that people will share their experiences and recommend it to others.

**Reporter:** How much does Fast Active cost with the discount?

**Dr. Abiola:** We've reached a successful agreement with the Director of the Association of Rheumatologists to offer a 50% discount to our customers. Fortunately, the experts recognize the importance of making this product accessible to everyone, not just a select few. We've promised not to sell our product to other manufacturers or export it abroad. Fast Active is intended exclusively for Nigeria.